Read time: 4 minutes Lung cancer screening guidelines were first issued by the United States Preventive Services Task Force in 2013 to help doctors find lung cancer in its earliest
Lung cancer experts from Johns Hopkins Kimmel Cancer Center dive into the how and why behind targeted therapy, immunotherapy, and radiation therapy. Touching on improvements to
LUNGevity blogs share personal stories, research updates, scientific meeting takeaways, policy news, and much more. Joining our Email List will help you stay updated on these
In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches
Currently, lung cancer screening using low-density computed tomography (LDCT) scans is available as a tool to screen for lung cancer in individuals at high risk of developing the
LUNGevity is excited to announce the launch of the LUNGevity Early Lung Cancer Center (ELCC). The ELCC was created to accelerate the development of early detection and early
While participating in clinical trials can provide substantial benefits to people with lung cancer, the resources required to do so may pose significant hurdles, especially to
A recent court case called Braidwood Management Inc. v. Becerra has received a lot of attention in the public health and cancer patient advocate communities. Current law requires
Our lung tissue is made of different kinds of cells, including neuroendocrine cells. If these cells develop changes in their genome, they can begin to grow out of control and
The point at which lung cancer is diagnosed plays a key role in treatment and survival. The average 5-year survival rate for lung cancer diagnosed while still localized (stage I)
Participating in a clinical trial gives patients the ability to try the newest treatments that otherwise are not available. There are many ongoing clinical trials testing new lung cancer treatments, including targeted therapies, chemotherapy, radiation therapy, and immunotherapy, alone and in combination.
Paul K. Paik, MD, medical oncologist and researcher at Memorial Sloan Kettering Cancer Center and a member of LUNGevity’s Scientific Advisory Board, sat down to talk about what squamous cell lung cancer is and where we stand with treatment options for this disease.